Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Daniel Eiger

8PUBLICATIONS

26CO-AUTHORS

Environmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Solid tumours

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|Nov 08, 2023

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.

Diogo Martins-Branco, Marie Kassapian, Véronique Debien

|Jun 28, 2022

Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.

Jens Huober, Carlos H Barrios, Naoki Niikura

|Jun 10, 2022

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.

Chau Dang, Michael S Ewer, Suzette Delaloge

|Apr 03, 2021

The Exciting New Field of HER2-Low Breast Cancer Treatment.

Daniel Eiger, Elisa Agostinetto, Rita Saúde-Conde

|Mar 20, 2020

Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer.

Daniel Eiger, Mariana Brandão, Evandro de Azambuja

|Mar 14, 2020

The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).

Daniel Eiger, Marcio Wagner, Noam F Pondé

Pageof 2

Frequent Collaborators

4 joint publications

Evandro de Azambuja

1 joint publications

Daniel Arcuschin de Oliveira

1 joint publications

Renato Leão de Oliveira

1 joint publications

Murilo Costa Sousa

1 joint publications

Mireille Darc Cavalcante Brandão

1 joint publications

Renato Santos de Oliveira Filho

1 joint publications

Marcio Wagner

1 joint publications

Noam F Pondé

1 joint publications

Melanie S Nogueira

1 joint publications

Laurence Buisseret

Frequent Collaborators

4 joint publications

Evandro de Azambuja

1 joint publications

Daniel Arcuschin de Oliveira

1 joint publications

Renato Leão de Oliveira

1 joint publications

Murilo Costa Sousa

Top Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on : Dec 11, 2017

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on : Jun 13, 2014

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on : May 24, 2024

See more related videos

Top Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on : Dec 11, 2017

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on : Jun 13, 2014

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on : May 24, 2024

See more related videos